Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||Advanced Solid Tumor||no benefit||Docetaxel + MK-5108||Phase I||Actionable||In a Phase I clinical trial, the combination of MK-5108 and Taxotere (docetaxel) did not demonstrate improved efficacy over MK-5108 monotherapy in patients with advanced solid tumors, and toxicity of the combination prevented achievement of target therapeutic exposure levels (PMID: 26620496).||26620496|